The child living with spinal muscular atrophy (SMA) type 2 had less fatigue and improved functional scores as time went on. The use of a gait exoskeleton appears to lead to benefits in terms of ...
"Decreasing AMMO [active maximal mouth opening] over time is seen most often in patients with SMA type 2 with an estimated reduction of almost 1 mm per year...At this point, we propose that ...
– Phase 3 trial is a randomized, double-blind, placebo-controlled trial of apitegromab as add-on to background SMN therapy in non-ambulatory Type 2/3 SMA – Trial design is informed by the positive ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Topline results from a phase 3 clinical ...
Some patients with later-onset spinal muscular atrophy (SMA) type 2 and type 3 had improved motor function when the investigational monoclonal antibody apitegromab was added to their treatment, the ...
The new report is based on real-world data from a patient registry and shows some patients even regain motor function under treatment with nusinersen for spinal muscular atrophy (SMA). A new ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a ...
If you have a child with SMA Type 3 (SMA3), there are some extra steps you’ll need to take to make sure that their school gives them the environment they need to learn and flourish academically as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback